Bavarian Nordic Crescita futura

Criteri Future verificati 0/6

Si prevede che il fatturato e gli utili di Bavarian Nordic diminuiscano rispettivamente di 1.8% e 24% all'anno. Si prevede che l'EPS diminuisca di 23.7% all'anno. Il rendimento del capitale proprio è previsto a 6.1% tra 3 anni.

Informazioni chiave

-24.0%

Tasso di crescita degli utili

-23.70%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	20.3%
Tasso di crescita dei ricavi	-1.8%
Rendimento futuro del capitale proprio	6.08%
Copertura analitica	Low
Ultimo aggiornamento	17 Nov 2025

Aggiornamenti recenti sulla crescita futura

Bavarian Nordic A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 08

Recent updates

Bavarian Nordic A/S (CPH:BAVA) Held Back By Insufficient Growth Even After Shares Climb 38%

Jul 28

Earnings Working Against Bavarian Nordic A/S' (CPH:BAVA) Share Price

Jun 13

Here's Why Shareholders May Want To Be Cautious With Increasing Bavarian Nordic A/S' (CPH:BAVA) CEO Pay Packet

Apr 03

Bavarian Nordic's (CPH:BAVA) Soft Earnings Are Actually Better Than They Appear

Mar 13

Bavarian Nordic A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 08

Chikungunya Vaccine Launch And Market Expansion Will Open Opportunities But Mpox Demand Uncertainties Could Pose Risks

Feb 10 The chikungunya vaccine launch and expansion into new markets could significantly drive revenue and broaden customer base.

Getting In Cheap On Bavarian Nordic A/S (CPH:BAVA) Is Unlikely

Dec 14

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Nov 16

Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher

Aug 26

Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models

Aug 25

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Aug 09

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Jul 11

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

May 12

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 09

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Feb 26

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Jan 03

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Dec 10

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Nov 15

Previsioni di crescita degli utili e dei ricavi

CPSE:BAVA - Stime future degli analisti e dati finanziari passati (DKK Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2027	5,689	852	1,185	1,342	2
12/31/2026	5,528	734	1,100	1,274	2
12/31/2025	6,009	1,646	1,955	2,128	1
9/30/2025	6,887	2,445	1,284	3,132	N/A
6/30/2025	6,455	1,423	-434	1,767	N/A
3/31/2025	6,231	1,321	-921	1,128	N/A
12/31/2024	5,716	988	262	1,950	N/A
9/30/2024	6,070	1,119	279	1,580	N/A
6/30/2024	6,083	707	882	1,958	N/A
3/31/2024	6,642	984	1,028	1,769	N/A
12/31/2023	7,062	1,475	142	1,119	N/A
9/30/2023	5,906	723	-793	751	N/A
6/30/2023	5,533	1,076	-979	568	N/A
3/31/2023	4,083	301	-1,344	-18	N/A
12/31/2022	3,151	-347	-1,162	220	N/A
9/30/2022	2,404	-599	-1,345	-109	N/A
6/30/2022	1,849	-693	-1,342	-101	N/A
3/31/2022	1,683	-606	-1,477	-215	N/A
12/31/2021	1,898	-465	-1,417	-358	N/A
9/30/2021	1,583	-737	-1,541	-663	N/A
6/30/2021	1,693	-629	-1,279	-478	N/A
3/31/2021	2,022	-368	-727	20	N/A
12/31/2020	1,852	278	-135	572	N/A
9/30/2020	1,914	606	-1,613	981	N/A
6/30/2020	1,499	481	-1,970	623	N/A
3/31/2020	901	267	-2,427	227	N/A
12/31/2019	662	-347	-2,947	-276	N/A
9/30/2019	554	-402	-645	-262	N/A
6/30/2019	631	-271	N/A	-204	N/A
3/31/2019	616	-279	N/A	-152	N/A
12/31/2018	501	-362	N/A	-289	N/A
9/30/2018	360	-445	N/A	-467	N/A
6/30/2018	873	-151	N/A	-564	N/A
3/31/2018	1,184	5	N/A	-158	N/A
12/31/2017	1,370	181	N/A	216	N/A
9/30/2017	1,745	453	N/A	1,030	N/A
6/30/2017	1,463	225	N/A	880	N/A
3/31/2017	1,182	153	N/A	501	N/A
12/31/2016	1,007	31	N/A	268	N/A
9/30/2016	909	-54	N/A	-539	N/A
6/30/2016	536	-202	N/A	-345	N/A
3/31/2016	808	-115	N/A	-561	N/A
12/31/2015	1,021	59	N/A	105	N/A
9/30/2015	1,244	155	N/A	818	N/A
6/30/2015	1,390	186	N/A	815	N/A
3/31/2015	1,166	70	N/A	1,018	N/A
12/31/2014	1,217	26	N/A	339	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che gli utili di BAVA diminuiranno nei prossimi 3 anni ( -24% all'anno).

Guadagni vs Mercato: Si prevede che gli utili di BAVA diminuiranno nei prossimi 3 anni ( -24% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di BAVA diminuiranno nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che i ricavi di BAVA diminuiranno nei prossimi 3 anni ( -1.8% all'anno).

Ricavi ad alta crescita: Si prevede che i ricavi di BAVA diminuiranno nei prossimi 3 anni ( -1.8% all'anno).

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di BAVA sarà basso tra 3 anni ( 6.1 %).

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/11/18 16:24
Prezzo dell'azione a fine giornata	2025/11/18 00:00
Utili	2025/09/30
Utili annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Bavarian Nordic A/S è coperta da 12 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Jacob Lademann	Carnegie Investment Bank AB
Peter Verdult	Citigroup Inc
Thomas Bowers	Danske Bank

Bavarian Nordic Crescita futura

Criteri Future verificati 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Bavarian Nordic A/S Provides Earnings Guidance for the Full Year 2025

Price target decreased by 13% to kr.235

Consensus EPS estimates increase by 41%

Consensus EPS estimates fall by 33%

Bavarian Nordic A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Price target decreased by 8.5% to kr.279

Recent updates

Bavarian Nordic A/S Provides Earnings Guidance for the Full Year 2025

Bavarian Nordic Announces Changes to the Board of Directors

Nordic Capital Epsilon Sca Sicav-raif and and funds managed and advised by Permira Advisers Ltd cancelled the acquisition of Bavarian Nordic A/S (CPSE:BAVA).

Investor sentiment deteriorates as stock falls 22%

Bavarian Nordic Reports Positive Topline Data for Mpox/Smallpox Vaccine in Pediatric Population

Second quarter 2025 earnings released: EPS: kr.4.50 (vs kr.3.30 in 2Q 2024)

Bavarian Nordic A/S to Report Q3, 2026 Results on Nov 13, 2026

Nordic Capital Epsilon Sca Sicav-raif and and funds managed and advised by Permira Advisers Ltd proposed to acquire Bavarian Nordic A/S (CPSE:BAVA) for DKK 18.1 billion.

Bavarian Nordic A/S (CPH:BAVA) Held Back By Insufficient Growth Even After Shares Climb 38%

Bavarian Nordic in Takeover Talks, Shares Rally

New minor risk - Share price stability

Investor sentiment improves as stock rises 28%

Price target decreased by 13% to kr.235

Bavarian Nordic A/S Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine

Earnings Working Against Bavarian Nordic A/S' (CPH:BAVA) Share Price

CEO & President exercised options to buy kr.4.1m worth of stock.

New major risk - Earnings quality

First quarter 2025 earnings released: EPS: kr.2.70 (vs kr.1.50 loss in 1Q 2024)

High number of new directors

Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices

Consensus EPS estimates increase by 41%

New major risk - Revenue and earnings growth

Here's Why Shareholders May Want To Be Cautious With Increasing Bavarian Nordic A/S' (CPH:BAVA) CEO Pay Packet

Bavarian Nordic A/S Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine

Bavarian Nordic's (CPH:BAVA) Soft Earnings Are Actually Better Than They Appear

Consensus EPS estimates fall by 33%

Bavarian Nordic A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Bavarian Nordic A/S Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older

CEO & President exercised options to buy kr.2.1m worth of stock.

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Bavarian Nordic A/S Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older

Price target decreased by 8.5% to kr.279

New major risk - Revenue and earnings growth

Chikungunya Vaccine Launch And Market Expansion Will Open Opportunities But Mpox Demand Uncertainties Could Pose Risks

Price target decreased by 8.3% to kr.278

Consensus EPS estimates fall by 10%

Getting In Cheap On Bavarian Nordic A/S (CPH:BAVA) Is Unlikely

Employee-Elected Member of the Board exercised options to buy kr.481k worth of stock.

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Investor sentiment deteriorates as stock falls 18%

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Price target increased by 9.0% to kr.312

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold kr.24m worth of stock

CEO & President exercised options to buy kr.24m worth of stock.

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Consensus EPS estimates increase by 56%

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher

Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models

Price target increased by 8.7% to kr.286

Second quarter 2024 earnings: Revenues exceed analyst expectations

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

New major risk - Share price stability

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Investor sentiment improves as stock rises 18%

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Investor sentiment improves as stock rises 18%

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)